Who Pays for Drug Quality?
This study examines how pharmaceutical costs for higher quality drugs are shared between insurers and consumers. Who bears these costs has important implications for patient access to better drugs, and for differences in access to higher quality pharmaceuticals. We investigate these issues using data from two large drug product classes: non-steroidal anti-inflammatory drugs (NSAIDs) and antidepressants. We find that insurers shift the drug costs associated with higher quality onto consumers for antidepressants but share in the costs of higher quality for NSAIDs. This suggests that patients’ cost burden, hence access, to higher quality drugs may vary across drug product classes.
Year of publication: |
2010
|
---|---|
Authors: | Chen, Jie ; Rizzo, John A |
Published in: |
Eastern Economic Journal. - Palgrave Macmillan, ISSN 0094-5056. - Vol. 36.2010, 2, p. 239-254
|
Publisher: |
Palgrave Macmillan |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
FEMALE EMPLOYMENT AND FERTILITY IN RURAL CHINA
Fang, Hai, (2010)
-
THE RETURNS TO EDUCATION IN CHINA: EVIDENCE FROM THE 1986 COMPULSORY EDUCATION LAW
Fang, Hai, (2012)
-
Financing Constraints and Investment: New Evidence from Hospital Industry Data.
Calem, Paul S, (1995)
- More ...